Clinical PotentialSIL-204 has demonstrated anti-tumor activity in five different KRAS mutated cancer types and inhibition across eight different KRAS mutations, supporting its clinical potential and expanding its market opportunity.
Preclinical SuccessSilexion recently announced additional highly positive preclinical data finding SIL-204 demonstrated 97% tumor growth inhibition in a previously untested KRAS mutated line and successfully showed inhibition in both pancreatic and colorectal cancers.
Regulatory SupportThe FDA awarding daraxonrasib a CNPV suggests the FDA is highly supportive of the KRAS targeting approach, indicating potential support for Silexion's IND filing in the U.S.